TY  - JOUR
AU  - Cobo Dols, Manuel
AU  - Beato Zambrano, Carmen
AU  - Cabezon-Gutierrez, Luis
AU  - Chicas-Sett, Rodolfo
AU  - Blancas Lopez-Barajas, Maria Isabel
AU  - Garcia Navalon, Francisco Javier
AU  - Firvida Perez, Jose Luis
AU  - Serrano Bermudez, Gala
AU  - Togores Torres, Pilar
AU  - Delgado Mingorance, Ignacio
AU  - Giraldo Marin, Alexandra
AU  - Libran Oriol, Anna
AU  - Paredes Lario, Alfredo
AU  - Sanchez Maurino, Pedro
AU  - Higuera Gomez, Oliver
AU  - Moreno Munoz, Diana
AU  - Huerta Gonzalez, Ibone
AU  - Sanz-Yague, Almudena
AU  - Soler Lopez, Begona
PY  - 2021
DO  - 10.1136/bmjspcare-2020-002816
SN  - 2045-435X
UR  - https://hdl.handle.net/10668/25895
T2  - Bmj supportive & palliative care
AB  - Objectives Naloxegol is a peripherally acting mu-opioid receptor antagonist (PAMORA) for treatment of opioid-induced constipation (OIC). The main objective was to analyse the long-term efficacy, quality of life (QOL) and safety of naloxegol in...
LA  - en
PB  - Bmj publishing group
KW  - constipation
KW  - cancer
KW  - pain
KW  - Induced bowel dysfunction
KW  - Pooled analysis
KW  - Noncancer pain
KW  - Prevalence
KW  - Pathophysiology
KW  - Validation
KW  - Management
KW  - Disorders
KW  - Severity
TI  - One-year efficacy and safety of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: KYONAL study
TY  - research article
ER  -